6878 related articles for article (PubMed ID: 11299792)
1. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
[TBL] [Abstract][Full Text] [Related]
3. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
[TBL] [Abstract][Full Text] [Related]
4. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.
Diaconu CC; Szathmári M; Kéri G; Venetianer A
Br J Cancer; 1999 Jun; 80(8):1197-203. PubMed ID: 10376972
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of TT-232 a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Keri G
Anticancer Res; 1999; 19(4B):3265-8. PubMed ID: 10652622
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
Tejeda M; Gaál D; Csuka O; Kéri G
Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
[TBL] [Abstract][Full Text] [Related]
10. Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Szúts T; Keri G
Anticancer Res; 2000; 20(2A):1023-7. PubMed ID: 10810391
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.
Pellizzari Tregno F; Sau A; Pezzola S; Geroni C; Lapenta C; Spada M; Filomeni G; Bonanno E; Federici G; Caccuri AM
Eur J Cancer; 2009 Sep; 45(14):2606-17. PubMed ID: 19665369
[TBL] [Abstract][Full Text] [Related]
13. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism.
Giammarioli AM; Maselli A; Casagrande A; Gambardella L; Gallina A; Spada M; Giovannetti A; Proietti E; Malorni W; Pierdominici M
Cancer Res; 2008 Jul; 68(13):5291-300. PubMed ID: 18593930
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia.
Pintér E; Helyes Z; Németh J; Pórszász R; Pethö G; Thán M; Kéri G; Horváth A; Jakab B; Szolcsányi J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):142-50. PubMed ID: 12122501
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
16. Azidothymidine inhibits melanoma cell growth in vitro and in vivo.
Humer J; Ferko B; Waltenberger A; Rapberger R; Pehamberger H; Muster T
Melanoma Res; 2008 Oct; 18(5):314-21. PubMed ID: 18781129
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
19. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
[TBL] [Abstract][Full Text] [Related]
20. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Sun BS; Wang JH; Liu LL; Gong SL; Redmond HP
J Surg Oncol; 2007 Sep; 96(3):241-8. PubMed ID: 17469118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
